Found: 2796
Select item for more details and to access through your institution.
Evaluation of the influence of trastuzumab therapy on serum levels of HER-2 protein and breast cancer cell lines.
- Published in:
- Menopausal Review / Przegląd Menopauzalny, 2024, v. 23, n. 2, p. 57, doi. 10.5114/pm.2024.139607
- By:
- Publication type:
- Article
Phase II clinical trial of docetaxel and trastuzumab for HER2-positive advanced extramammary Paget's disease (EMPD-HER2DOC).
- Published in:
- Oncologist, 2024, v. 29, n. 9, p. e1201, doi. 10.1093/oncolo/oyae097
- By:
- Publication type:
- Article
Managed Care Considerations in the Treatment of HER2-Positive Advanced Breast Cancer: A Closer Look at Recent Advances for Improved Patient Outcomes.
- Published in:
- Journal of Managed Care Medicine, 2024, v. 27, n. 2, p. 40
- By:
- Publication type:
- Article
A signal-seeking phase 2 study of Trastuzumab emtansine in tumours harbouring HER2 amplification or mutation.
- Published in:
- NPJ Precision Oncology, 2024, v. 8, n. 1, p. 1, doi. 10.1038/s41698-024-00698-4
- By:
- Publication type:
- Article
ペルツズマブ(遺伝子組換え)・トラスツズマブ (遺伝子組換え)・ボルヒアルロニダーゼ アルファ (遺伝子組換え)(フェスゴ<sup>®</sup>配合皮下注 MA,同 IN) の薬理学的特性及び臨床開発の経緯.
- Published in:
- Folia Pharmacologica Japonica, 2024, v. 159, n. 4, p. 241, doi. 10.1254/fpj.24022
- By:
- Publication type:
- Article
Impact of Value-Driven Healthcare Strategies for Biosimilar Adoption: The Singapore Story.
- Published in:
- PharmacoEconomics - Open, 2024, v. 8, n. 5, p. 679, doi. 10.1007/s41669-024-00491-w
- By:
- Publication type:
- Article
Long-Term Outcomes of Adjuvant Trastuzumab for 9 Weeks or 1 Year for ERBB2-Positive Breast Cancer: A Secondary Analysis of the SOLD Randomized Clinical Trial.
- Published in:
- JAMA Network Open, 2024, v. 7, n. 8, p. e2429772, doi. 10.1001/jamanetworkopen.2024.29772
- By:
- Publication type:
- Article
Changes in Heterosexual Couples' Sexuality During the First Two Years After Breast Cancer Surgery: A Longitudinal Descriptive Study.
- Published in:
- Sexuality & Disability, 2024, v. 42, n. 3, p. 661, doi. 10.1007/s11195-024-09854-x
- By:
- Publication type:
- Article
Real-world Outcomes of Dual HER2 Blockade Therapy in Metastatic HER2-Positive Breast Cancer: from Induction to Maintenance.
- Published in:
- Drugs - Real World Outcomes, 2024, v. 11, n. 3, p. 413, doi. 10.1007/s40801-024-00438-x
- By:
- Publication type:
- Article
Targeting ITGβ3 to Overcome Trastuzumab Resistance through Epithelial–Mesenchymal Transition Regulation in HER2-Positive Breast Cancer.
- Published in:
- International Journal of Molecular Sciences, 2024, v. 25, n. 16, p. 8640, doi. 10.3390/ijms25168640
- By:
- Publication type:
- Article
Preventing broken hearts in women with breast cancer: a concise review on chemotherapy-mediated cardiotoxicity.
- Published in:
- Canadian Journal of Physiology & Pharmacology, 2024, v. 102, n. 9, p. 487, doi. 10.1139/cjpp-2023-0358
- By:
- Publication type:
- Article
Trastuzumab Deruxtecan in HER2-Positive Breast Cancer.
- Published in:
- Journal of Clinical Outcomes Management, 2022, v. 29, n. 4, p. 132, doi. 10.12788/jcom.0104
- By:
- Publication type:
- Article
Breast cancer overview: Current treatments.
- Published in:
- Practice Nursing, 2009, v. 20, n. 6, p. 282, doi. 10.12968/pnur.2009.20.6.42553
- By:
- Publication type:
- Article
Economic evaluations of trastuzumab in HER2-positive metastatic breast cancer: a systematic review and critique.
- Published in:
- European Journal of Health Economics, 2014, v. 15, n. 1, p. 93, doi. 10.1007/s10198-013-0459-2
- By:
- Publication type:
- Article
Cost-effectiveness of lapatinib plus capecitabine in women with HER2+ metastatic breast cancer who have received prior therapy with trastuzumab.
- Published in:
- European Journal of Health Economics, 2012, v. 13, n. 5, p. 589, doi. 10.1007/s10198-011-0323-1
- By:
- Publication type:
- Article
Trastuzumab and Doxorubicin-Related Cardiotoxicity and the Cardioprotective Role of Exercise.
- Published in:
- Integrative Cancer Therapies, 2009, v. 8, n. 1, p. 17, doi. 10.1177/1534735408330717
- By:
- Publication type:
- Article
Ethynylation of Cysteine Residues: From Peptides to Proteins in Vitro and in Living Cells.
- Published in:
- Angewandte Chemie, 2020, v. 132, n. 27, p. 11054, doi. 10.1002/ange.202002626
- By:
- Publication type:
- Article
Oxetane Grafts Installed Site-Selectively on Native Disulfides to Enhance Protein Stability and Activity In Vivo.
- Published in:
- Angewandte Chemie, 2017, v. 129, n. 47, p. 15159, doi. 10.1002/ange.201708847
- By:
- Publication type:
- Article
Design of Switchable Chimeric Antigen Receptor T Cells Targeting Breast Cancer.
- Published in:
- Angewandte Chemie, 2016, v. 128, n. 26, p. 7646, doi. 10.1002/ange.201601902
- By:
- Publication type:
- Article
Rational Design of a Humanized Glucagon-Like Peptide-1 Receptor Agonist Antibody.
- Published in:
- Angewandte Chemie, 2015, v. 127, n. 7, p. 2154, doi. 10.1002/ange.201410049
- By:
- Publication type:
- Article
Trastuzumab-DM1: A Clinical Update of the Novel Antibody-Drug Conjugate for HER2-Overexpressing Breast Cancer.
- Published in:
- Molecular Medicine, 2012, v. 18, n. 11, p. 1473, doi. 10.2119/molmed.2012.00302
- By:
- Publication type:
- Article
Tumour exosomes inhibit binding of tumour-reactive antibodies to tumour cells and reduce ADCC.
- Published in:
- Cancer Immunology, Immunotherapy, 2011, v. 60, n. 5, p. 639, doi. 10.1007/s00262-011-0979-5
- By:
- Publication type:
- Article
Physical and biological properties of homophilic therapeutic antibodies.
- Published in:
- Cancer Immunology, Immunotherapy, 2011, v. 60, n. 4, p. 507, doi. 10.1007/s00262-010-0952-8
- By:
- Publication type:
- Article
In vivo activity of novel anti-ErbB2 antibody chA21 alone and with Paclitaxel or Trastuzumab in breast and ovarian cancer xenograft models.
- Published in:
- Cancer Immunology, Immunotherapy, 2011, v. 60, n. 3, p. 339, doi. 10.1007/s00262-010-0937-7
- By:
- Publication type:
- Article
Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/ neu-positive tumour cells.
- Published in:
- Cancer Immunology, Immunotherapy, 2009, v. 58, n. 6, p. 915, doi. 10.1007/s00262-008-0607-1
- By:
- Publication type:
- Article
A CD80-transfected human breast cancer cell variant induces HER-2/neu-specific T cells in HLA-A*02-matched situations in vitro as well as in vivo.
- Published in:
- Cancer Immunology, Immunotherapy, 2005, v. 54, n. 2, p. 129, doi. 10.1007/s00262-004-0583-z
- By:
- Publication type:
- Article
Immunoprevention and immunotherapy of cancer in ageing.
- Published in:
- Cancer Immunology, Immunotherapy, 2005, v. 54, n. 2, p. 93, doi. 10.1007/s00262-004-0539-3
- By:
- Publication type:
- Article
Production and validation of the pharmacokinetics of a single-chain Fv fragment of the MGR6 antibody for targeting of tumors expressing HER-2.
- Published in:
- Cancer Immunology, Immunotherapy, 2001, v. 49, n. 12, p. 679, doi. 10.1007/s002620000162
- By:
- Publication type:
- Article
Trastuzumab (herceptin): a retrospective analysis of the effects of long-term application in a series of patients with breast cancer.
- Published in:
- Archives of Gynecology & Obstetrics, 2014, v. 290, n. 4, p. 733, doi. 10.1007/s00404-014-3261-1
- By:
- Publication type:
- Article
Trastuzumab clears HER2/neu-positive isolated tumor cells from bone marrow in primary breast cancer patients.
- Published in:
- Archives of Gynecology & Obstetrics, 2012, v. 285, n. 2, p. 485, doi. 10.1007/s00404-011-1954-2
- By:
- Publication type:
- Article
Observation of de Novo Bladder Dysfunction under Treatment with Her2-neu Antibodies.
- Published in:
- Urologia Internationalis, 2011, v. 86, n. 1, p. 80, doi. 10.1159/000317441
- By:
- Publication type:
- Article
Pertuzumab-Mediated Cardiotoxicity: A Single Center Study.
- Published in:
- Sakarya Tıp Dergisi, 2023, v. 13, n. 2, p. 314, doi. 10.31832/smj.1163527
- By:
- Publication type:
- Article
Heavy chain dimers stabilized by disulfide bonds are required to promote in vitro assembly of trastuzumab.
- Published in:
- BMC Molecular & Cell Biology, 2020, p. 1, doi. 10.1186/s12860-019-0244-x
- By:
- Publication type:
- Article
HER2-positive breast cancer - Available anti-HER2 therapies and new agents under investigation.
- Published in:
- Journal of Pre-Clinical & Clinical Research, 2020, v. 14, n. 2, p. 44, doi. 10.26444/jpccr/122068
- By:
- Publication type:
- Article
Accuracy of self-reported cancer treatment data in young breast cancer survivors.
- Published in:
- Journal of Patient-Reported Outcomes, 2019, v. 3, n. 1, p. N.PAG, doi. 10.1186/s41687-019-0114-5
- By:
- Publication type:
- Article
Immunotherapy: A killer combination.
- Published in:
- Nature Reviews Immunology, 2012, v. 12, n. 4, p. 231, doi. 10.1038/nri3204
- By:
- Publication type:
- Article
Antibody and antibody fragments site-specific conjugation using new Q-tag substrate of bacterial transglutaminase.
- Published in:
- Cell Death Discovery, 2024, v. 10, n. 1, p. 1, doi. 10.1038/s41420-024-01845-3
- By:
- Publication type:
- Article
Redox Status Response of Physical Exercise Training in Women with Breast Cancer during Trastuzumab Therapy.
- Published in:
- Healthcare (2227-9032), 2022, v. 10, n. 10, p. N.PAG, doi. 10.3390/healthcare10102039
- By:
- Publication type:
- Article
Erratum.
- Published in:
- 2018
- Publication type:
- Correction Notice
Overall Survival Benefit from Trastuzumab-Based Treatment in HER2-Positive Metastatic Breast Cancer: A Retrospective Analysis.
- Published in:
- Oncology Research & Treatment, 2018, v. 41, n. 7, p. 450, doi. 10.1159/000488202
- By:
- Publication type:
- Article
Optimization of ultrasound parameters for microbubble-nanoliposome complex-mediated delivery.
- Published in:
- Ultrasonography, 2015, v. 34, n. 4, p. 297, doi. 10.14366/usg.15009
- By:
- Publication type:
- Article
Identification of Genes Predicting Poor Response of Trastuzumab in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Long-term irreversible trastuzumab-induced cardiotoxicity for metastatic breast cancer in a patient without cardiac risk factors.
- Published in:
- 2017
- By:
- Publication type:
- Case Study
The Prevention and Management of Cardiovascular Complications of Chemotherapy in Patients with Cancer.
- Published in:
- American Journal of Cardiovascular Drugs, 2005, v. 5, n. 4, p. 233, doi. 10.2165/00129784-200505040-00003
- By:
- Publication type:
- Article
VP07 Collaboratively Modelling The Impact Of Interventions Retrospectively.
- Published in:
- 2017
- By:
- Publication type:
- Abstract
GLOBAL PRICING POLICIES AND COST-EFFECTIVENESS OF TRASTUZUMAB IN LATIN AMERICA.
- Published in:
- International Journal of Technology Assessment in Health Care, 2015, v. 31, n. 1/2, p. 1, doi. 10.1017/S026646231500029X
- By:
- Publication type:
- Article
IMPLICATIONS OF GLOBAL PRICING POLICIES ON ACCESS TO INNOVATIVE DRUGS: THE CASE OF TRASTUZUMAB IN SEVEN LATIN AMERICAN COUNTRIES.
- Published in:
- International Journal of Technology Assessment in Health Care, 2015, v. 31, n. 1/2, p. 2, doi. 10.1017/S0266462315000094
- By:
- Publication type:
- Article
Budget impact analysis of trastuzumab in early breast cancer: A hospital district perspective.
- Published in:
- International Journal of Technology Assessment in Health Care, 2010, v. 26, n. 2, p. 163, doi. 10.1017/S0266462310000103
- By:
- Publication type:
- Article
Trastuzumab resistance induces EMT to transform HER2<sup>+</sup> PTEN<sup>−</sup> to a triple negative breast cancer that requires unique treatment options.
- Published in:
- Scientific Reports, 2015, p. 15821, doi. 10.1038/srep15821
- By:
- Publication type:
- Article
Physical Intimacy of Breast Cancer Cells with Mesenchymal Stem Cells Elicits Trastuzumab Resistance through Src Activation.
- Published in:
- Scientific Reports, 2015, p. 13744, doi. 10.1038/srep13744
- By:
- Publication type:
- Article